Rhopressa
(Netarsudil Ophthalmic)Preclinical
Rhopressa is one of 6 small molecule programs targeting Rhegmatogenous Retinal Detachment. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
5
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
7 competitors in Rhegmatogenous Retinal Detachment
#DrugCompanyPhaseTrials
1Actigall
AbbVieApproved
Lovenox
SanofiPreclinical
Intravitreal Topotecan
UUnity Health Toronto
Phase 2
Rhopressa
FFalcon
Preclinical
Rhopressa
FFalcon
Preclinical
Sulfur Hexafluoride
TTurku University Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Regulatory
FDA Approval Timeline[4]
Dec 18, 2017
RHOPRESSA
NDA NDA208254
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Netarsudil Ophthalmic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]